Mark
Mark SELF
Administration & Human Resources Manager

Background

Education, tourism, gardening and languages.

Interests

Languages and travelling

Favourite holiday destination

Edinburgh, Scotland

About cilcare
Who we are
Our team
Scientific advisors
Hearing loss & Aging connection
External Innovation

Pharmacokinetics & distribution

PK & Distribution
Bioanalysis
Vectors & gene therapy distribution
Biomarker studies

Behavioral tests

Tinnitus detection
GPIAS & PPI
Hyperacusis

Delivery capabilities

Transtympanic
Intracochlear
Systemic

Surgery

Inner ear surgery
Cochlear implantation
Brain Electrode implantation
Other otic surgery

Screening / dose selection for ototoxicity or otoprotection

In vitro on Otic cell line
Ex vivo on Cochlear explants
In vivo in Zebrafish

Formulation

Formulation for otic delivery

Animal models

Noise-induced hearing loss
Synaptopathy
Cisplatin-induced ototoxicity
Antibiotic-induced ototoxicity
Ouabain-induced auditory neuropathy
Salicylate-induced tinnitus
Other disease & transgenic models
Rodent & large species

Our missions

In vivo studies

Auditory efficacy studies
Auditory tolerance & safety studies
Auditory phenotyping studies
GLP Ototoxicity studies / GLP Toxicology & Toxicokinetics

Modalities

Small molecules, peptides, antibodies, large molecules
Gene & cell therapies
Cochlear implants, implantable devices, drug-eluting electrodes

Electrophysiology & electroacoustic

ABR
DPOAE
Wave I to V analysis
CAP & unicellular electrophysiology

Ear assessment

Otoscopy
Tympanometry
Gross middle ear assessment

Pathology & histopathology

Histology of the ear
Cytocochleogram
Histology of other organs
Microscopy & imaging

Molecular biology & biochemistry

Biochemistry
Molecular biology

OUR MISSIONS

IN VITRO / EX VIVO / IN VIVO EFFICACY

FORMULATION & DISTRIBUTION

OTOTOXICITY

CLINICAL AUDITORY BIOMARKER

> In vitro / ex vivo assays

In vitro on Otic cell line
Ex vivo on Cochlear explants

> In vivo models

Zebrasfish, Rodents & Large species
Noise-induced hearing loss
Synaptopathy
Cisplatin-induced ototoxicity
Antibiotic-induced ototoxicity
Ouabain-induced auditory neuropathy
Salicylate-induced tinnitus
Other diseases & transgenic models

> Hearing measurements & behavioral tests

Otoscopy
ABR
Wave I to V analysis
DPOAE
Tympanometry
Tinnitus detection
GPIAS & PPI
Hyperacusis
CAP & unicellular electrophysiology
Molecular Biology & Biochemistry
Preclinical biomarkers
Auditory phenotyping

> Pathology & Histopathology

Gross middle ear assessment
Histology of the ear
Cytocochleogram
Histology of other organs
Microscopy & imaging

> Surgery

Inner ear surgery
Cochlear implantation
Brain Electrode implantation
Other otic surgery

> Formulation for otic delivery

> Otic drug, vector & gene therapy administration

Transtympanic
Intracochlear
Systemic

> Inner ear PK studies

> PK studies for other therapeutic indications

> Vectors & gene therapy distribution

> Therapeutic modalities

Small molecules, peptides, antibodies, large molecules
Gene & cell therapies
Cochlear implants, implantable devices, drug-eluting electrodes

> Auditory tolerance & safety studies

> GLP Ototoxicity studies / GLP Toxicology & Toxicokinetics

> Human hearing measurements

> Clinical biomarker studies

Therapeutics
Our missions
Our pipeline
Cochlear synaptopathy
Our clinical studies
Auditory Analytics